Alisertib, a jewel of Takeda’s $8.8 billion acquisition of Millennium Pharmaceuticals back in 2008, failed to make the grade in a Phase III lymphoma trial, forcing the Japanese drugmaker to pull the plug and pivot to other indications.

…read more

Source: One of Takeda’s big cancer bets flops in a Phase III lymphoma trial


0 No comments